会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明授权
    • Unsynchronized radio imaging
    • 不同步的无线电成像
    • US08847813B2
    • 2014-09-30
    • US13301762
    • 2011-11-21
    • Igor BausovGerald StolarczykLarry G. StolarczykTito SanchezJoseph Duncan
    • Igor BausovGerald StolarczykLarry G. StolarczykTito SanchezJoseph Duncan
    • G01S13/88G01S13/00G01V3/12
    • G01S13/003G01V3/12
    • An unsynchronized acoustic or radio-frequency (RF) computed tomography (CT) imaging system with matched, but independent, continuous wave (CW) transmitters and receivers configured to radiate acoustic or RF transmissions in a plurality of vector paths through solid geologic material. A computer calculates and displays tomographic images constructed from individual acoustic or RF path signal travel time or attenuation measurements logged from registered locations from the CW transmitters and receivers after their being shuttled amongst a number of different transmitter and receiver perspectives available around said geologic material to generate data necessary for computed tomography. Each of the transmitters and receivers include independent unsynchronized crystal oscillators rated at 10-ppm or better frequency uncertainty to produce and to detect CW radio frequency (RF) transmissions.
    • 具有匹配但独立的连续波(CW)发射机和接收机的不同步的声学或射频(RF)计算机断层摄影(CT)成像系统,其被配置为通过固体地质材料辐射多个向量路径中的声学或RF传输。 一台计算机计算并显示从单独的声学或RF路径信号行进时间构建的断层摄影图像,或者在CW发射机和接收机在从所述地质材料周围可用的多个不同的发射机和接收机视角之间穿梭之前从注册的位置记录的衰减测量结果 计算机断层扫描所需的数据。 每个发射器和接收器包括额定为10 ppm或更高频率不确定度的独立的不同步晶体振荡器,以产生和检测CW射频(RF)传输。
    • 13. 发明申请
    • Hydroxylated nebivolol metabolites
    • 羟基化的奈比洛尔代谢物
    • US20070014733A1
    • 2007-01-18
    • US11342497
    • 2006-01-30
    • John O'DonnellWalter OwensJoseph DuncanAndrew ShawJinn Wu
    • John O'DonnellWalter OwensJoseph DuncanAndrew ShawJinn Wu
    • A61K31/353A61L9/04
    • C07D311/58A61K31/353
    • Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.
    • 急性给药后羟化的奈比洛尔代谢物以浓度依赖的方式增加人内皮细胞制剂的NO释放。 此外,羟基化的奈比洛尔代谢物,包括但不限于4-羟基-6,6'-二氟 - ,4-羟基-5-苯酚-6,6'-二氟和4-羟基-8-苯基-6,6 “二氟”具有增加慢性给药后人体内皮细胞NO释放能力的能力。 本发明提供羟基化的奈比洛尔代谢物和包含奈比洛尔和/或至少一种羟基化的奈必洛尔代谢物和/或用于治疗心血管疾病的至少一种另外的化合物或其药学上可接受的盐的组合物。 此外,本发明提供了治疗和/或预防血管疾病的方法,其通过施用能够将治疗有效量的一氧化氮释放到受血管疾病影响的靶位点的奈比洛尔的羟基化代谢物。 此外,本发明涉及治疗和/或预防给予至少一种羟基化的奈必洛尔代谢物的偏头痛。 本发明还可以与代谢综合征病症联合使用或作为单一治疗代用综合征病症使用。
    • 18. 发明申请
    • Glucuronidated nebivolol metabolites
    • 葡萄糖醛酸化的奈比洛尔代谢物
    • US20070014734A1
    • 2007-01-18
    • US11342889
    • 2006-01-30
    • John O'DonnellWalter OwensJoseph DuncanAndrew Shaw
    • John O'DonnellWalter OwensJoseph DuncanAndrew Shaw
    • A61K31/7048A61L9/04
    • A61K45/06A61K31/7012A61K31/7048A61K2300/00
    • This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.
    • 本发明提供了用于治疗心血管疾病的葡糖醛酸化奈必洛尔代谢物和葡糖苷酸化奈必洛尔代谢物的药物组合物。 此外,本发明还提供在药学上可接受的载体中包含奈比洛尔和/或至少一种葡萄糖醛酸化的奈必洛尔代谢物和/或至少一种其它活性化合物的组合物。 本发明还提供了治疗和/或预防血管疾病的方法,其通过施用能够将治疗有效量的一氧化氮释放到受血管疾病影响的靶位的奈比洛尔的至少一种葡糖醛酸化代谢物。 此外,本发明涉及治疗和/或预防给予至少一种奈非洛尔的葡糖醛酸化代谢物的偏头痛。 本发明还可以与代谢综合征病症联合使用或作为单一治疗代用综合征病症使用。